(Total Views: 607)
Posted On: 10/20/2020 7:50:46 AM
Post# of 154119
SAF,
I believe you are 100% correct, that DSMC expects endpoint to be met, possibly at 75% enrollment, arguing that 50% enrollment was very close.
Follow-up also argues that placebo patients continue to die post 28 days at markedly great frequency than leronlimab arm.
We all want leronlimab approved yesterday, but these are very positive developments IMO
I believe you are 100% correct, that DSMC expects endpoint to be met, possibly at 75% enrollment, arguing that 50% enrollment was very close.
Follow-up also argues that placebo patients continue to die post 28 days at markedly great frequency than leronlimab arm.
We all want leronlimab approved yesterday, but these are very positive developments IMO
(6)
(0)
